制药行业资助的转移性非小细胞肺癌临床试验证据强度与其他资助来源的比较
该研究检索PubMed 2012–2017年转移性NSCLC临床试验报告,共分析477项研究(制药行业资助275项,其他来源202项),纳入85,328例患者。制药行业资助研究证据更强(p<0.001),评估更多创新疗法(72% vs 36%,p<0.001),开放获取论文比例更高(63% vs 47%,p<0.001),两组在实验组优效性报告偏倚和偏倚风险方面无显著差异。
要点
- 制药行业资助的转移性NSCLC试验证据强度更高(p<0.001)。
- 制药行业资助试验评估创新疗法比例更高(72% vs 36%,p<0.001)。
- 两组在阳性结果报告倾向和偏倚风险上无显著差异。
核心结论
- 与其它资助来源相比,制药行业资助的肺癌领域研究证据更强,评估更多昂贵和创新疗法,且似乎同等强调阳性和阴性结果。
研究设计与样本
- 检索PubMed 2012–2017年发表的转移性NSCLC临床试验报告,将研究分为制药行业资助组和其他来源资助组,主要终点为比较两组证据强度。
- 共分析477项研究,其中制药行业资助275项,其他来源资助202项,总计纳入85,328例患者。
主要发现
- 制药行业资助研究纳入患者64,434例,其他来源资助研究纳入20,894例(p<0.001)。
- 制药行业资助研究证据强度更强(p<0.001)。
- 制药行业资助研究评估创新疗法比例72%,其他来源为36%(p<0.001)。
- 制药行业资助研究开放获取论文比例63%,其他来源为47%(p<0.001)。
- 两组在实验组优效性报告或偏倚风险方面无显著差异。
临床怎么用
- 解读转移性NSCLC临床试验证据时,可关注资助来源对证据强度和創新疗法评估的影响。
- 制药行业资助研究并不必然导致阳性结果报告偏倚或更高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Clinical trials are expensive and often require funding from the pharmaceutical industry (PI). We aimed to compare studies funded by the PI with those funded by other sources in terms of costs, reported results, and strength of evidence. METHODS: We searched PubMed for clinical trial reports on metastatic NSCLC published between 2012 and 2017. We divided all the studies into two groups: studies funded by the PI and those funded by other sources. The primary end point was to compare the evidence strength of each group. The secondary end points were to compare the number of patients included, the number and costs of innovative drugs studied, whether there was preferential reporting of positive results in the experimental arm, and the risk of bias. RESULTS: We found 3004 studies, and of these, we analyzed 477 studies (275 sponsored by the PI and 202 funded by other sources). A total of 85,328 patients overall were included (64,434 in studies sponsored by the PI and 20,894 in studies with other funding sources; p < 0.001). The studies funded by the PI had stronger evidence (p < 0.001), evaluated more innovative therapies (72% versus 36%; p < 0.001), and resulted in a higher proportion of open-access manuscripts (63% versus 47%; p < 0.001). There was no considerable difference regarding the reporting of experimental arm superiority or the risk of bias between the two groups. CONCLUSIONS: Compared with studies from other sources of funding, those funded by the PI in the lung cancer field collected stronger evidence, assessed more expensive and innovative therapies, and seemed to equally emphasize positive and negative results.
引用
- de Souza Gutierres B, Aguiar PN, Dourado BB, et al. Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. J Thorac Oncol. 2020. PMID: 32217131. doi:10.1016/j.jtho.2020.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。